S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
66,000% upside on tiny biotech? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
66,000% upside on tiny biotech? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
66,000% upside on tiny biotech? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
Enterprise Products: 7.33% Yield and 26-Years of Dividend Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
A Tech Stock You've Never Heard Of Just Hit The Rally Button
Challenges Hit Broadcom Stock, But Analysts See EPS Growth
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Is New IPO Instacart Already Hitting Speed Bumps?
Prospect Capital Corporation: A Gold Nugget or Value Trap?
66,000% upside on tiny biotech? (Ad)
52-week Low Names To Tip The Upside Scale In Your Favor
Seagen, Activision Blizzard rise; Scholastic, Intel fall, Friday, 9/22/2023
NASDAQ:HCM

HUTCHMED (HCM) Stock Forecast, Price & News

$15.83
+0.59 (+3.87%)
(As of 09/22/2023 ET)
Compare
Today's Range
$15.55
$16.11
50-Day Range
$12.20
$16.48
52-Week Range
$7.39
$21.28
Volume
149,072 shs
Average Volume
100,391 shs
Market Capitalization
$2.76 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$50.00

HUTCHMED MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
215.9% Upside
$50.00 Price Target
Short Interest
Healthy
0.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.03) to ($0.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

Medical Sector

720th out of 966 stocks

Pharmaceutical Preparations Industry

331st out of 450 stocks


HCM stock logo

About HUTCHMED (NASDAQ:HCM) Stock

HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, a spleen tyrosine kinase inhibitor for hematological cancers and certain chronic immune diseases; and HMPL-689 for isoform PI3Kd (phosphoinositide 3'-kinase delta). In addition, it develops Tazemetostat, an inhibitor of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-760, an Bruton's tyrosine kinase inhibitor; HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-295 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; HMPL-A83, an investigational IgG4-type humanized anti-CD47 monoclonal antibody; and Epitinib (HMPL-813) and Theliatinib (HMPL-309) inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. The company was incorporated in 2000 and is headquartered in Central, Hong Kong.

HCM Price History

HCM Stock News Headlines

[BREAKING] Pentagon to Spend Billions on "Living Missile"
Air Force Magazine calls it "transformational." The Wall Street Journal calls it one of the Pentagon's "highest priorities." National Defense Magazine reports "Eye-popping budget" for it. This small company won the first contract to build them!
HCM - HUTCHMED (China) Limited
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
HCM.L - HUTCHMED (China) Limited
Our Update On Hutchmed China's Progress
HUTCHMED (China) Limited (HCM)
See More Headlines
Receive HCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HUTCHMED and its competitors with MarketBeat's FREE daily newsletter.

HCM Company Calendar

Today
9/22/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HCM
Employees
2,025
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$50.00
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$50.00
Forecasted Upside/Downside
+215.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$426.41 million
Book Value
$3.68 per share

Miscellaneous

Free Float
167,927,000
Market Cap
$2.76 billion
Optionable
Not Optionable
Beta
1.01

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Chi Keung To ACGI (Age 71)
    B.Sc., BSc, M.B.A., MBA, Exec. Chairman
    Comp: $85k
  • Dr. Wei-Guo Su B.Sc. (Age 65)
    Ph.D., CEO, Chief Scientific Officer & Exec. Director
    Comp: $1.97M
  • Mr. Chig Fung Cheng BEc (Age 56)
    CA, CFO & Exec. Director
    Comp: $886k
  • Ms. Edith Shih BSE (Age 71)
    C.S., CGP, EdM, FCIS, FCS, FCS(PE), M.A., MA, Company Sec. & Non-Exec. Director
  • Dr. Karen Jane Atkin (Age 57)
    Exec. VP & COO
  • Mr. Kin Hung Lee M.B.A. (Age 46)
    Sr. VP of Corp. Fin. & Devel.
  • Mr. Charles George Rupert Nixon (Age 53)
    Group Gen. Counsel
  • Ms. Selina Zhang
    Sr. VP of Global HR
  • Dr. Qingmei Wang Ph.D. (Age 60)
    Sr. VP of Bus. Devel. & Strategic Alliances
  • Mr. Hong Chen (Age 53)
    Sr. VP & Chief Commercial Officer- China













HCM Stock - Frequently Asked Questions

Should I buy or sell HUTCHMED stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HUTCHMED in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HCM shares.
View HCM analyst ratings
or view top-rated stocks.

What is HUTCHMED's stock price forecast for 2023?

2 analysts have issued 1 year price objectives for HUTCHMED's shares. Their HCM share price forecasts range from $50.00 to $50.00. On average, they expect the company's share price to reach $50.00 in the next year. This suggests a possible upside of 215.9% from the stock's current price.
View analysts price targets for HCM
or view top-rated stocks among Wall Street analysts.

How have HCM shares performed in 2023?

HUTCHMED's stock was trading at $14.78 at the beginning of the year. Since then, HCM shares have increased by 7.1% and is now trading at $15.83.
View the best growth stocks for 2023 here
.

Are investors shorting HUTCHMED?

HUTCHMED saw a decrease in short interest in the month of August. As of August 31st, there was short interest totaling 928,000 shares, a decrease of 10.8% from the August 15th total of 1,040,000 shares. Based on an average daily volume of 108,800 shares, the days-to-cover ratio is currently 8.5 days.
View HUTCHMED's Short Interest
.

What ETFs hold HUTCHMED's stock?

ETFs with the largest weight of HUTCHMED (NASDAQ:HCM) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA).

What other stocks do shareholders of HUTCHMED own?

Based on aggregate information from My MarketBeat watchlists, some companies that other HUTCHMED investors own include Telford Homes (TEF), AbbVie (ABBV), Exelixis (EXEL), GW Pharmaceuticals (GWPH), Premier Oil (PMO), CRISPR Therapeutics (CRSP), AT&T (T), Johnson & Johnson (JNJ), NVIDIA (NVDA) and Weyerhaeuser (WY).

When did HUTCHMED IPO?

(HCM) raised $100 million in an IPO on Thursday, March 17th 2016. The company issued 6,100,000 shares at a price of $16.33 per share. BofA Merrill Lynch and Deutsche Bank Securities acted as the underwriters for the IPO and Stifel, Canaccord Genuity, Panmure Gordon and CITIC CLSA were co-managers.

What is HUTCHMED's stock symbol?

HUTCHMED trades on the NASDAQ under the ticker symbol "HCM."

Who are HUTCHMED's major shareholders?

HUTCHMED's stock is owned by a variety of retail and institutional investors. Top institutional investors include M&G Investment Management Ltd. (4.35%), Schroder Investment Management Group (2.66%), Bellevue Group AG (1.04%), UniSuper Management Pty Ltd (0.33%), Goldman Sachs Group Inc. (0.31%) and State Street Corp (0.25%).

How do I buy shares of HUTCHMED?

Shares of HCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is HUTCHMED's stock price today?

One share of HCM stock can currently be purchased for approximately $15.83.

How much money does HUTCHMED make?

HUTCHMED (NASDAQ:HCM) has a market capitalization of $2.76 billion and generates $426.41 million in revenue each year.

How many employees does HUTCHMED have?

The company employs 2,025 workers across the globe.

How can I contact HUTCHMED?

HUTCHMED's mailing address is 48TH FLOOR CHEUNG KONG CENTER 2 QUEEN`S ROAD CENTRAL, HONG KONG K3, . The official website for the company is www.chi-med.com. The company can be reached via phone at 852-2121-3888, via email at ir@chi-med.com, or via fax at 852-2128-1778.

This page (NASDAQ:HCM) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -